目的 探讨蒲地蓝消炎口服液联合重组人干扰素α1b注射液治疗普通型手足口病的临床疗效。方法 选取2013年10月-2015年10月在苏州市立医院进行治疗的普通型手足口病患儿97例，按照治疗方式的不同分为对照组（42例）和治疗组（55例）。对照组肌肉注射重组人干扰素α1b注射液，10 μg/次，1次/d。治疗组在对照组基础上口服蒲地蓝消炎口服液，5～10 mL/次，3次/d。两组患儿均治疗7 d。观察两组的临床疗效，比较两组的症状消失时间和进食情况。结果 治疗后，对照组和治疗组的总有效率分别为80.95%、94.55%，两组比较差异有统计学意义（P<0.05）。治疗后，治疗组退热时间、皮疹消退时间、口腔黏膜充血和溃疡恢复时间、总病程均明显短于对照组，两组比较差异有统计学意义（P<0.05）。治疗3、5 d后，对照组进食为“好”的占比分别为42.86%、69.05%；治疗组进食为“好”的占比分别为56.36%、81.82%，两组比较差异有统计学意义（P<0.05）。结论 蒲地蓝消炎口服液联合重组人干扰素α1b注射液治疗普通型手足口病具有较好的临床疗效，可改善临床症状，缩短病程，改善患儿进食情况，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Pudilan Xiaoyan Oral Liquid combined with Recombinant Human Interferon α1b Injection in treatment of children with common hand-foot-and-mouth disease. Methods Children (97 cases) with common hand-foot-and-mouth disease in Suzhou Municipal Hospital from October 2013 to October 2015 were enrolled in this study. According to the difference treatment plan, children were divided into control group (42 cases) and treatment group (55 cases). Children in the control group were im administered with Recombinant Human Interferon α1b Injection, 10 μg/time, once daily. Children in the treatment group were po administered with Pudilan Xiaoyan Oral Liquid on the basis of the control group, 5-10 mL/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacies were evaluated, and symptom disappearance time and eating condition in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 94.55%, respectively, and there was difference between two groups (P<0.05). After treatment, pyretolysis time, skin rash subsided time, oral mucosal congestion and ulcer recovery time, and disease duration in the treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). After treatment for 3 d and 5 d, the percentage of eating condition as "good" in the control group were 42.86% and 69.05%, respectively, but the percentage of eating condition as "good" in the treatment group were 56.36% and 81.82%, respectively, and there was difference between two groups (P<0.05). Conclusion Pudilan Xiaoyan Oral Liquid combined with Recombinant Human Interferon α1b Injection has clinical curative effect in treatment of children with common hand-foot-and-mouth disease, can improve clinical symptom, shorten disease duration, and improve eating condition, which has a certain clinical application value.